N. Woodward

发表

Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.

D. Vagenas, Kirsty Rickett, K. Roberts, 2020, The Cochrane database of systematic reviews.

Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape

S. Loi, R. Bell, J. Beith, 2016, Asia-Pacific journal of clinical oncology.

Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.

J. Coward, G. Ho, N. Woodward, 2016, Critical reviews in oncology/hematology.

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.

W. Eiermann, H. Rugo, Y. Im, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer

J. Sanmugarajah, S. Pathmanathan, R. Ladwa, 2018, Clinical breast cancer.

Management of patients treated with pertuzumab in the Australian clinical practice setting

D. Tsoi, L. Pugliano, N. Woodward, 2016, Asia-Pacific journal of clinical oncology.

Single institution outcomes of treatment of severe aplastic anaemia

P. Mollee, J. Rowell, L. Lockwood, 2001, Internal medicine journal.

Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2‐non‐amplified metastatic breast cancer

E. Lim, J. Beith, A. Redfern, 2018, Asia-Pacific journal of clinical oncology.

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy

W. Eiermann, H. Rugo, I. C. Tudor, 2019, JNCI cancer spectrum.

Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.

D. Vagenas, Kirsty Rickett, K. Roberts, 2020, The Cochrane database of systematic reviews.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia

A. Redfern, A. Chan, D. Tsoi, 2021, Asia-Pacific journal of clinical oncology.

Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).

J. Beith, A. Redfern, R. D. de Boer, 2019, Clinical breast cancer.

Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report

Wen Xu, Kristopher Rallah-Baker, N. Woodward, 2014, BMC Ophthalmology.

Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.

M. Chatfield, Kirsty Rickett, K. Roberts, 2022, The Cochrane database of systematic reviews.

Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.

R. Greer, Kirsty Rickett, K. Roberts, 2017, Critical reviews in oncology/hematology.

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors

L. Naumovski, P. Ansell, J. Sachdev, 2020, Investigational New Drugs.

Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm

E. Lim, J. Beith, A. Redfern, 2018, Asia-Pacific journal of clinical oncology.

Poor Muscle Status, Dietary Protein Intake, Exercise Levels, Quality of Life and Physical Function in Women with Metastatic Breast Cancer at Chemotherapy Commencement and during Follow-Up

M. Crichton, L. Teleni, C. Shannon, 2023, Current oncology.

Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape

R. Bell, J. Beith, A. Redfern, 2016, Asia-Pacific journal of clinical oncology.

Potential Impact of the 2016 Consensus Definitions of Sepsis and Septic Shock on Future Sepsis Research

Michael Bailey, A. Purdue, Anthony Delaney, 2017, Annals of emergency medicine.

Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b

W. Tilley, T. Hickey, J. Armes, 2018, British Journal of Cancer.

Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab.

T. Marwick, C. Jenkins, R. Leano, 2009, American heart journal.

Letter to the editor: re Lu et al.

D. Vagenas, Kirsty Rickett, K. Roberts, 2020, Supportive Care in Cancer.

The Q-IMPROvE (Queensland-IMplementation of PRecision Oncology in brEast cancer) pilot study.

N. Waddell, O. Kondrashova, A. M. McCart Reed, 2023, medRxiv.

Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen

J. Armes, C. Snell, C. Pyke, 2017, Journal of Clinical Pathology.

Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b

W. Tilley, T. Hickey, J. Armes, 2018, British Journal of Cancer.

Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.

R. Greer, Kirsty Rickett, K. Roberts, 2017, Critical reviews in oncology/hematology.